Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities

Ítems similars

• Bcr-Abl tyrosine kinase inhibitors- current status
  per: Mughal, Anum, et al.
  Publicat: (2013)
• The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
  per: Hantschel, Oliver, et al.
  Publicat: (2007)
• Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
  per: Carofiglio, Francesca, et al.
  Publicat: (2020)
• Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
  per: Byrgazov, Konstantin, et al.
  Publicat: (2016)
• Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia
  per: Leoni, Veronica, et al.
  Publicat: (2015)